Real-world outcomes with durvalumab (durva) after chemoradiotherapy (CRT) in patients with unresectable stage III NSCLC (SPOTLIGHT)

被引：3
|
作者：
Mooradian, M. [1 ,2 ]
Allen, A. [3 ]
Cai, L. [3 ]
Xiao, Y. [3 ]
Chander, P. [3 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] AstraZeneca, Gaithersburg, MD USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.02.143
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
116P
引用
收藏
页码：S86 / S86
页数：1
相关论文
共 50 条
  • [21] Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
    Vansteenkiste, Johan F.
    Naidoo, Jarushka
    Faivre-Finn, Corinne
    Ozguroglu, Mustafa
    Villegas, Augusto
    Daniel, Davey
    Murakami, Shuji
    Hui, Rina
    Lee, Ki Hyeong
    Cho, Byoung Chul
    Kubota, Kaoru
    Broadhurst, Helen
    Wadsworth, Catherine
    Newton, Michael
    Thiyagarajah, Piruntha
    Antonia, Scott J.
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (03):
  • [22] Durvalumab After Chemoradiotherapy for Patients With Unresectable Stage III NSCLC: The PACIFIC-R Study
    Zhao, Binghao
    Li, Huanzhang
    Ma, Wenbin
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : e38 - e39
  • [23] Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients
    Julian Taugner
    Lukas Käsmann
    Chukwuka Eze
    Alexander Rühle
    Amanda Tufman
    Niels Reinmuth
    Thomas Duell
    Claus Belka
    Farkhad Manapov
    Investigational New Drugs, 2021, 39 : 1189 - 1196
  • [24] Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients
    Taugner, Julian
    Kaesmann, Lukas
    Eze, Chukwuka
    Ruehle, Alexander
    Tufman, Amanda
    Reinmuth, Niels
    Duell, Thomas
    Belka, Claus
    Manapov, Farkhad
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (04) : 1189 - 1196
  • [25] Treatment patterns and efficacy of durvalumab maintenance after CRT in real-world NSCLC patients
    Taugner, J.
    Kaesmann, L.
    Eze, C.
    Floersch, B.
    Guggenberger, J.
    Tufman, A.
    Reinmuth, N.
    Duell, T.
    Belka, C.
    Manapov, F.
    RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S968 - S968
  • [26] Early Treatment Failure Of Consolidation Durvalumab for Unresectable Stage III NSCLC: A Real-World Canadian Cohort
    Gibson, A.
    Dean, M.
    Elegbede, A.
    Pabani, A.
    Bebb, G.
    Cheung, W.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S282 - S283
  • [27] Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer Patients Treated with Durvalumab after Chemoradiotherapy
    Oh, H. -J.
    Park, C. -K.
    Kim, Y. -C.
    Kim, Y. -H.
    Ahn, S. -J.
    Jeong, W. G.
    Lee, J. Y.
    Lee, J. C.
    Choi, C. M.
    Ji, W.
    Song, S. Y.
    Choi, J.
    Lee, S. Y.
    Kim, H.
    Lee, S. Y.
    Park, J.
    Yoon, S. H.
    Joo, J. H.
    Oh, I. -J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S294 - S295
  • [28] The Incidence of Brain Metastasis and Radiation Pneumonitis With Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC
    Kim, Y.
    Choi, Y-K
    Kwak, Y-K
    Lee, Y-H
    Kim, S-H
    Sung, S-Y
    Son, S-H
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S281 - S281
  • [29] PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
    Girard, N.
    Smit, H. J. M.
    Sibille, A.
    McDonald, F.
    Mornex, F.
    Garassino, M. C. C.
    Filippi, A. R.
    Peters, S.
    Field, J. K.
    Christoph, D. C.
    Fietkau, R.
    Haakensen, V. D.
    Bar, J.
    Chouaid, C.
    Bray, V.
    Kao, S.
    Sawyer, W.
    Allen, A.
    Licour, M.
    Garrido, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S939 - S940
  • [30] Pacific-R Real-World Study: Treatment Duration and Interim Analysis of Progression-Free Survival in Unresectable Stage III NSCLC Patients Treated with Durvalumab After Chemoradiotherapy
    Christoph, Daniel
    Girard, N.
    Smit, H. J. M.
    Sibille, A.
    Mcdonald, F.
    Mornex, F.
    Garassino, M. C.
    Filippi, A. R.
    Peters, S.
    Field, J. K.
    Haakensen, V. Drageset
    Bar, J.
    Chouaid, C.
    Bray, V.
    Kao, S.
    Sawyer, W.
    Allen, A.
    Licour, M.
    Garrido, P.
    Fietkau, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 151 - 151
12345